Logo image of AFMD

AFFIMED NV (AFMD) Stock Fundamental Analysis

NASDAQ:AFMD - Nasdaq - NL0015001ZQ0 - Common Stock - Currency: USD

0.96  -0.14 (-12.73%)

After market: 0.98 +0.02 (+2.08%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AFMD. AFMD was compared to 567 industry peers in the Biotechnology industry. AFMD has a bad profitability rating. Also its financial health evaluation is rather negative. AFMD is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

AFMD had negative earnings in the past year.
AFMD had a negative operating cash flow in the past year.
In the past 5 years AFMD always reported negative net income.
AFMD had a negative operating cash flow in each of the past 5 years.
AFMD Yearly Net Income VS EBIT VS OCF VS FCFAFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

With a Return On Assets value of -175.10%, AFMD is not doing good in the industry: 87.13% of the companies in the same industry are doing better.
AFMD's Return On Equity of -406.92% is on the low side compared to the rest of the industry. AFMD is outperformed by 76.72% of its industry peers.
Industry RankSector Rank
ROA -175.1%
ROE -406.92%
ROIC N/A
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
AFMD Yearly ROA, ROE, ROICAFMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

AFMD's Gross Margin of 789.74% is amongst the best of the industry. AFMD outperforms 99.82% of its industry peers.
In the last couple of years the Gross Margin of AFMD has declined.
The Profit Margin and Operating Margin are not available for AFMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 789.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
AFMD Yearly Profit, Operating, Gross MarginsAFMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

2

2. Health

2.1 Basic Checks

AFMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AFMD remains at a similar level compared to 1 year ago.
AFMD has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AFMD has a worse debt to assets ratio.
AFMD Yearly Shares OutstandingAFMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
AFMD Yearly Total Debt VS Total AssetsAFMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

AFMD has an Altman-Z score of -4.07. This is a bad value and indicates that AFMD is not financially healthy and even has some risk of bankruptcy.
AFMD has a Altman-Z score (-4.07) which is comparable to the rest of the industry.
AFMD has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of AFMD (0.35) is worse than 72.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Altman-Z -4.07
ROIC/WACCN/A
WACC8.39%
AFMD Yearly LT Debt VS Equity VS FCFAFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M 150M

2.3 Liquidity

A Current Ratio of 1.93 indicates that AFMD should not have too much problems paying its short term obligations.
With a Current ratio value of 1.93, AFMD is not doing good in the industry: 76.19% of the companies in the same industry are doing better.
A Quick Ratio of 1.93 indicates that AFMD should not have too much problems paying its short term obligations.
AFMD has a worse Quick ratio (1.93) than 74.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.93
AFMD Yearly Current Assets VS Current LiabilitesAFMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

4

3. Growth

3.1 Past

AFMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.15%, which is quite impressive.
AFMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -95.39%.
The Revenue for AFMD have been decreasing by -19.00% on average. This is quite bad
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%

3.2 Future

The Earnings Per Share is expected to grow by 11.18% on average over the next years. This is quite good.
AFMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.57% yearly.
EPS Next Y40.97%
EPS Next 2Y29.01%
EPS Next 3Y19.02%
EPS Next 5Y11.18%
Revenue Next Year-81.84%
Revenue Next 2Y-23.09%
Revenue Next 3Y14.98%
Revenue Next 5Y35.57%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AFMD Yearly Revenue VS EstimatesAFMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AFMD Yearly EPS VS EstimatesAFMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -50 -100 -150 -200

0

4. Valuation

4.1 Price/Earnings Ratio

AFMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AFMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AFMD Price Earnings VS Forward Price EarningsAFMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AFMD Per share dataAFMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

AFMD's earnings are expected to grow with 19.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.01%
EPS Next 3Y19.02%

0

5. Dividend

5.1 Amount

No dividends for AFMD!.
Industry RankSector Rank
Dividend Yield N/A

AFFIMED NV

NASDAQ:AFMD (5/2/2025, 8:00:00 PM)

After market: 0.98 +0.02 (+2.08%)

0.96

-0.14 (-12.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-02 2025-05-02/amc
Earnings (Next)06-09 2025-06-09
Inst Owners22.64%
Inst Owner Change-6.12%
Ins Owners6.01%
Ins Owner ChangeN/A
Market Cap14.62M
Analysts84
Price Target12.24 (1175%)
Short Float %4.81%
Short Ratio6.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.56%
Min EPS beat(2)-10.88%
Max EPS beat(2)1.75%
EPS beat(4)3
Avg EPS beat(4)4.52%
Min EPS beat(4)-10.88%
Max EPS beat(4)14.22%
EPS beat(8)4
Avg EPS beat(8)1.65%
EPS beat(12)7
Avg EPS beat(12)6.57%
EPS beat(16)8
Avg EPS beat(16)-11.38%
Revenue beat(2)0
Avg Revenue beat(2)-90.72%
Min Revenue beat(2)-92.4%
Max Revenue beat(2)-89.04%
Revenue beat(4)0
Avg Revenue beat(4)-85.87%
Min Revenue beat(4)-92.4%
Max Revenue beat(4)-74.24%
Revenue beat(8)2
Avg Revenue beat(8)-47.19%
Revenue beat(12)4
Avg Revenue beat(12)-23.39%
Revenue beat(16)7
Avg Revenue beat(16)-15.7%
PT rev (1m)-11.76%
PT rev (3m)-22.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.48%
EPS NY rev (1m)0%
EPS NY rev (3m)-2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)20%
Revenue NY rev (1m)0%
Revenue NY rev (3m)20%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.7
P/FCF N/A
P/OCF N/A
P/B 0.75
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-5.18
EYN/A
EPS(NY)-2.68
Fwd EYN/A
FCF(TTM)-5.77
FCFYN/A
OCF(TTM)-5.73
OCFYN/A
SpS0.07
BVpS1.28
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -175.1%
ROE -406.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 789.74%
FCFM N/A
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
F-Score1
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.61%
Cap/Sales 60.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.93
Altman-Z -4.07
F-Score1
WACC8.39%
ROIC/WACCN/A
Cap/Depr(3y)175.27%
Cap/Depr(5y)145.6%
Cap/Sales(3y)18.76%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
EPS Next Y40.97%
EPS Next 2Y29.01%
EPS Next 3Y19.02%
EPS Next 5Y11.18%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%
Revenue Next Year-81.84%
Revenue Next 2Y-23.09%
Revenue Next 3Y14.98%
Revenue Next 5Y35.57%
EBIT growth 1Y42.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.28%
OCF growth 3YN/A
OCF growth 5YN/A